Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Five ways to beat German reimbursement

This article was originally published in Scrip

Executive Summary

Germany's new reimbursement system has tripped up a lot of companies since it arrived in January 2011. Boehringer struggled with its diabetes drug Tradjenta and, fearing it wouldn't get a premium price, decided against launching in Germany. Other firms have mis-timed dossier filings, chosen the wrong comparative treatments, or ignored the advice of advisors. And the problem is only going to bigger as the reimbursement authorities start retrospective assessments of drug classes. There may be a map for the German process but this only helps companies through the administrative process. To perform properly, firms need to tune-up their organizations and reshape internal attitudes.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel